Stockerblog.com Parkinson's Stocks
934 views
Rate Now:
average rating: 0.00 / 0 ratings
Created by stockerblog
DESCRIPTION:
Date updated:04-25-2007
Companies researching treatments and cures for this degenerative disorder of the central nervous system that impairs motor skills and speech.
-
TEVA
Teva Pharmaceutic - $52.79
- -0.17%
- $53.28
No Analysis added
-
CEGE
Cell Genesys - $0.36
- 0.00%
- $N/A
No Analysis added
-
NVS
Novartis Ag Ads - $55.60
- +0.40%
- $55.78
No Analysis added
-
ACAD
Acadia Pharmaceut - $1.23
- -4.65%
- $1.31
No Analysis added
-
SNY
Sanofi-aventis Sa - $37.96
- -1.22%
- $37.89
No Analysis added
-
SKYE
N/a - $25.55
- 0.00
- $25.55
No Analysis added
-
VRX
Valeant Pharma In - $32.69
- -0.40%
- $32.89
No Analysis added
- Top Professional Portfolios
- 1. Fidelity Contrafund - ...
- 2. Navellier & Associ...
- 3. Calamos Advisors
- 4. Argus Management
- 5. Charlie Munger
- show all
- Top Do-It-Yourself Portfolios
- » Joseph Russell Portfolio 1
- » Albo's First Portfolio
- » Darrell Werth Portfolio 1
- » Echo5Joker's Portfolio
- » jgroov Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
Dividend Stocks for the Week
By Jonas Elmerraji Posted on Dec. 1, 2009 After an earnings season that has brought a significant stream of dividend-increasers, stocks are taking a step back, with jus...
12.01.09 | 13:52 PM
This Week's 'Barron's' Roundup
By Roberto Pedone Posted on Dec. 1, 2009 Bullish and Bearish: Each week, Barron’s publishes bullish and bearish stories on a variety of stocks. We present summaries o...
12.01.09 | 12:23 PM
Cramer's Take on Headline Stocks...
Posted on Dec. 1, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is to gather as much in...
12.01.09 | 11:45 AM
Rocket Stocks for the Week
more articles
By Jonas Elmerraji Posted on Nov. 30, 2009 With Black Friday behind us and another data-heavy week ahead, it’s time to turn once again to Rocket Stocks, our list of b...
11.30.09 | 09:16 AM
Nymph's Trading Daily Trading Diary
04.13.09 | 01:10 AM From author
Trading Nymph
The Presidential/Political Thread
01.02.08 | 08:05 AM From author
Dave Cox
Options-Selling Short
12.01.09 | 06:48 AM From author
Knocka
General market Technical Analysi...
more forums
11.14.07 | 22:55 PM From author
ZA
Q.
How to delete a portfolio
12.01.09 | 18:41 PM Asked by
bariloche
Q.
Steel....playing catch up now. ...
03.24.09 | 11:34 AM Asked by
dgbkr
A. The only one I own : SLX,
too hard pick a winner out all of them
today 's lists
52-Week Lows
Here is a list of some of the biggest stocks that hit 52-week lows on Dec. 1, 2009. more
Dogs of the Dow
Here are the 10 stocks in the Dow Jones Industrial Average stocks with the highest yields as of the market close on Dec. 1, 2009. more
Tomorrow's Ex-Dividend Stocks
Below is a list of some of the companies that have their ex-dividend date Wednesday, Dec. 2, 2009. What is the ex-dividend date? The ex-dividend date of a stock is th... more
05/01/2007 17:31 PM CDT Asked by Dark Knight 212
In addition to the companies you listed, I suggest you look at the British biotech firm Amarin (AMRN - Last Trade: 0.68 Change: -0.025). AMRN has ongoing Phase II clinical testing of Miraxion and AMR-101 both for the treatment of Parkinson's Disease.
Amarin recently dropped more than 85 percent on poor results in Phase III tests of Miraxion for Huntington's disease.
After an 85% drop the stock bears watching because they have 4 other drugs in their pipeline that are on track, 29 million dollars cash, no debt and they have 30% insider and 25% institutional ownership.
Management will be providing an update to investors on the progress, plans and timelines for Amarin’s pipeline of products at two upcoming investor conferences. Rodman & Renshaw on May 15th and Banc of America on June 1st. Both of these investor presentations will be webcast so you can listen in. More information about the specifics of the webcasts will be issued in advance of each conference.
Full Disclosure: I own AMRN.